ALTERATIONS IN COAGULATION AND FIBRINOLYSIS IN LUNG CANCER PATIENTS

1987 ◽  
Author(s):  
M A Ruiz ◽  
A Estellés ◽  
I Marugán ◽  
I Navarro ◽  
J Aznar ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Lung Tumor ◽  
Locally Advanced ◽  
Control Group ◽  
Lung Cancer Patients ◽  
Cancer Group ◽  
Plasmatic Coagulation ◽  
Fibrinolytic Parameters ◽  
Coagulation And Fibrinolysis

Lung cancer has commonly been associated with to both clinical problems of thromboembolism and to biological alterations in -coagulation and fibrinolysis.We evaluated some coagulation and fibrinolytic parameters of the plasmatic coagulation and fibrinolytic system (Fibrinopeptide A (-FPA-) for enzimoimmunoassay, immunological tissue plasminogen activator (t-PA) for enzimoimmunoassay, functional (t-PA) for -chromogenic substrate and functional t-PAinhibitor (PAI) in 40 non-operable lung cancer patients (Table I) comprising 39 males and one female, aged 45 to 67 (average 59). The results are compared with those from a control group of 20 healthy male volun-ters aged 32 to 58 (average 48).Table II shows the results obtained (mean ± SD) for the parameters found to be significantly different to those of the control group. An increase is seen in the levels of FPA, functional t-PA and PAI in the lung cancer group. In the case of the extensive -lung tumor patients, FPAfpa and t-PA levels are significantly higher than for the group of locally advanced neoplasmas.The plasma of lung cancer patients therefore shows fibrinolytic alterations and an increase in thromboplastin activity.

scholarly journals Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Blood to Distinguish Lung Cancer Patients from Healthy Subjects

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Xuming Zhu ◽  
Huizhu Song ◽  
Yan Chen ◽  
Feifei Han ◽  
Qiong Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Control Group ◽  
Healthy Individuals ◽  
Platelet To Lymphocyte Ratio ◽  
Lung Cancer Patients ◽  
Lymphocyte Ratio ◽  
Cancer Group ◽  
Level Group

Objective. Inflammation-driven markers play a crucial role in tumorigenesis and tumor progression. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in blood are systemic inflammatory response markers. Some reports have showed that NLR and PLR are related to a poor prognosis in patients with lung cancer. However, little studies have reported whether NLR and PLR can be diagnostic markers for lung cancer. The aim of the current study is to investigate the roles of NLR and PLR in diagnosing lung cancer. Methods. This study analyzed data from lung cancer patients and healthy individuals in Wuxi People’s Hospital Affiliated with Nanjing Medical University. The Mann–Whitney U test was performed to compare differences between the lung cancer group and the control group. Based on white blood cell (WBC) counts, both lung cancer patients and healthy individuals were divided into the low-level group, moderate-level group, and high-level group. The Kruskal-Wallis test was applied to compare differences of NLR and PLR among those groups with different WBC counts. Spearman correlation analysis was used to assess correlations. Receiver operating characteristic (ROC) curves were performed to determine diagnostic accuracy. Results. 210 patients diagnosed with lung cancer and 261 healthy subjects were enrolled in this study. Levels of NLR and PLR increased in the lung cancer group compared with the control group ( P < 0.001 ). For the lung cancer group, NLR levels could rise with the increasing of WBC levels ( P < 0.001 ) while PLR levels had no significant variation with the increasing of WBC levels ( P = 0.206 ). For the control group, NLR levels could rise with the increasing of WBC levels ( P < 0.001 ) while PLR levels would decline with the increasing of WBC levels ( P < 0.001 ). In the lung cancer group, both NLR and PLR had no significant correlations with aspartate transaminase, urea, and glucose. The area under the curve (AUC) with 95% confidence interval (95% CI) of NLR and PLR to distinguish lung cancer patients from healthy subjects was, respectively, 0.684 (0.634-0.735) and 0.623 (0.571-0.674). When NLR and PLR were combined, AUC (95% CI) increased to 0.691 (0.642-0.740). Conclusions. NLR and PLR alone have moderate ability to distinguish lung cancer patients from healthy subjects. Furthermore, combination forms of NLR and PLR can improve diagnostic ability.

scholarly journals miRNA-486 and miRNA-499 in human plasma evaluate the clinical stages of lung cancer and play a role as a tumor suppressor in lung tumorigeneisis not pathogenesis

2016 ◽  
Vol 11 (1) ◽  
pp. 264 ◽  
Author(s):  
Youchao Jia ◽  
Aimin Zang ◽  
Yanguang Feng ◽  
Xiao-Fang Li ◽  
Ke Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Statistical Significance ◽  
Small Cell ◽  
Expression Level ◽  
Control Group ◽  
Small Cell Lung ◽  
Lung Cancer Patients

<p class="Abstract">It was aimed to explore the expression level of miRNA-486 and miRNA-499 in the plasma of lung cancer patients and analysis their differences in expre-ssion. The expression level of both miRNA-486 and miRNA-499 in the plasma of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) were lower than that of the control group (p&lt;0.05) and the decrease was more obvious in NSCLC. Compare with the miRNA-499，expression quantity in NSCLC patients plasma. There was statistical significance difference (p&lt;0.05) between III～Ⅳstage and I～II stage. The expression quantity of miRNA in plasma of patients with extensive-stage SCLC was lower than that of patients with limited-stage SCLC (p&lt;0.05). The sensitivity and specificity of plasms miRNA-486 respectively were 88.5% and 83.3%. The expression of miRNA-499 and miRNA-486 in lung cancer patients were up-regulated, and might be closely related to the occurrence and prognosis of lung cancer, and might be used as potential screening and prognosis index for lung cancer.</p><p> </p>

scholarly journals Effect of respiratory training apparatus and vibration expectoration vest on expectoration in patients with lung cancer resection

2018 ◽  
Vol 5 (4) ◽  
pp. 285-289
Author(s):  
Xiao-Jing Guo ◽  
Li-Li Wei ◽  
Xin-Hui Li ◽  
Ning- Ning Yu ◽  
Shao-Bo Gao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Respiratory Function ◽  
Perioperative Period ◽  
Control Group ◽  
Observation Group ◽  
Pulmonary Atelectasis ◽  
Cancer Resection ◽  
Lung Cancer Patients ◽  
Respiratory Training

Abstract Objective The aim of this study was to explore the safe and effective method of expectoration in the preoperative period of patients with lung cancer resection and to promote the rehabilitation of patients. Methods A total of 100 cases of lung cancer patients undergoing elective surgery were divided into the observation group and the control group, with 50 cases in each group. The control group was treated with vibration expectoration vest for expectoration during the perioperative period, and the observation group was treated with respiratory function exerciser that has expectoration function in the perioperative period, three times a day, and the effect was evaluated after 5 days. Results The number of patients in the observation group after the first expectoration time was significantly less than that of the control group (P<0.001). Pain score, pulmonary atelectasis, and pulmonary infection rate of the observation group were significantly lower than those of the control group; the hospitalization time was significantly shorter than that of the control group; and the difference was statistically significant (P<0.05). Conclusions Lobectomy for lung cancer patients with perioperative respiratory training for respiratory function exercise, compared with conventional methods, is helpful for postoperative expectoration and to reduce the incidence of adverse events.

Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer Patients

2019 ◽  
Vol 20 (1) ◽  
pp. e1-e7 ◽  
Author(s):  
G. Daniel Grass ◽  
Arash O. Naghavi ◽  
Yazan A. Abuodeh ◽  
Bradford A. Perez ◽  
Thomas J. Dilling
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Definitive Chemoradiotherapy ◽  
Lung Cancer Patients

Mitigating differential baseline shifts in locally advanced lung cancer patients using an average anatomy model

2017 ◽  
Vol 44 (7) ◽  
pp. 3570-3578 ◽  
Author(s):  
Mehrsima Abdoli ◽  
Simon R. Van Kranen ◽  
Uros Stankovic ◽  
Maddalena M. G. Rossi ◽  
Jose S. A. Belderbos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Locally Advanced ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Locally Advanced Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document